NCT00140478

Mifepristone (RU-486) in Androgen Independent Prostate Cancer

A Phase II Study of Mifepristone (RU-486) in Androgen Independent Prostate Cancer With Correlative Assessment of Androgen Receptor Co-Repressor Proteins

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effects (good and bad) that mifepristone has on patients with androgen independent prostate cancer.

Detailed description

Patients will receive mifepristone, 200mg orally once a day. One treatment cycle is 28 days long. Patients will remain on treatment unless their cancer gets worse or they develop intolerable side effects. At the end of each cycle a physical examination, routine blood tests, and hormone levels will be performed. After every 3 cycles, one or more of the following will be performed: bone scan, chest x-ray, CT scan or MRI.

Conditions

• Prostate Cancer
• Adenocarcinoma of Prostate

Interventions

Type	Name	Description
DRUG	Mifepristone	200mg orally once daily

Timeline

• Start date: 2005-02-01
• Primary completion: 2006-06-01
• Completion: 2008-01-01
• First posted: 2005-09-01
• Last updated: 2009-12-09

Locations

4 sites across 1 country: United States